Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
Recursion (NASDAQ: RXRX) and Enamine have announced a collaboration to create AI-enabled targeted compound libraries for drug discovery. The partnership combines Recursion's AI/ML platform (Recursion OS) with Enamine's REAL Space, the world's largest make-on-demand small molecule collection.
The collaboration has resulted in 10 enriched screening libraries comprising over 15,000 newly synthesized compounds, designed to accelerate drug discovery against 100 key clinical targets in challenging biological areas. By leveraging Recursion's AI technology to predict small molecule compatibility with protein targets, the partnership enables the creation of focused libraries that outperform traditional high-throughput screening collections.
As part of the research collaboration, Recursion gained access to tens of thousands of compounds for its internal discovery needs, while helping develop libraries of broad commercial interest. The curated libraries are now available through Enamine's website for customer hit-finding campaigns.
Recursion (NASDAQ: RXRX) e Enamine hanno annunciato una collaborazione per creare librerie di composti mirati abilitati dall'IA per la scoperta di farmaci. Il partenariato combina la piattaforma AI/ML di Recursion (Recursion OS) con il REAL Space di Enamine, la più grande collezione di piccole molecole su richiesta al mondo.
Questa collaborazione ha portato alla creazione di 10 librerie di screening arricchite composte da oltre 15.000 composti appena sintetizzati, progettate per accelerare la scoperta di farmaci contro 100 obiettivi clinici chiave in aree biologiche difficili. Sfruttando la tecnologia AI di Recursion per prevedere la compatibilità delle piccole molecole con i target proteici, il partenariato consente la creazione di librerie mirate che superano le tradizionali collezioni di screening ad alta capacità.
Come parte della collaborazione di ricerca, Recursion ha avuto accesso a decine di migliaia di composti per le proprie esigenze interne di scoperta, contribuendo allo stesso tempo allo sviluppo di librerie di ampio interesse commerciale. Le librerie curate sono ora disponibili attraverso il sito web di Enamine per campagne di ricerca di hit da parte dei clienti.
Recursion (NASDAQ: RXRX) y Enamine han anunciado una colaboración para crear bibliotecas de compuestos dirigidos habilitados por IA para el descubrimiento de fármacos. La asociación combina la plataforma AI/ML de Recursion (Recursion OS) con el REAL Space de Enamine, la colección de pequeñas moléculas bajo demanda más grande del mundo.
La colaboración ha dado como resultado 10 bibliotecas de cribado enriquecidas que comprenden más de 15,000 compuestos recién sintetizados, diseñadas para acelerar el descubrimiento de fármacos contra 100 objetivos clínicos clave en áreas biológicas desafiantes. Al aprovechar la tecnología de IA de Recursion para predecir la compatibilidad de pequeñas moléculas con objetivos proteicos, la asociación permite la creación de bibliotecas enfocadas que superan a las colecciones tradicionales de cribado de alto rendimiento.
Como parte de la colaboración de investigación, Recursion tuvo acceso a decenas de miles de compuestos para sus necesidades internas de descubrimiento, mientras ayudaba a desarrollar bibliotecas de amplio interés comercial. Las bibliotecas curadas ya están disponibles a través del sitio web de Enamine para campañas de búsqueda de hits por parte de los clientes.
Recursion (NASDAQ: RXRX)와 Enamine이 약물 발견을 위한 AI 기반의 타겟 화합물 라이브러리를 만들기 위한 협력관계를 발표했습니다. 이 파트너십은 Recursion의 AI/ML 플랫폼(Recursion OS)과 Enamine의 REAL Space, 세계에서 가장 큰 주문형 소분자 컬렉션을 결합합니다.
이번 협력의 결과로 10개의 강화된 스크리닝 라이브러리가 생성되었으며, 15,000개 이상의 새로 합성된 화합물로 구성되어 있습니다. 이 라이브러리는 어려운 생물학적 영역에서 100개의 주요 임상 타겟에 대한 약물 발견을 가속화하도록 설계되었습니다. Recursion의 AI 기술을 활용하여 소분자의 단백질 타겟과의 호환성을 예측함으로써, 이 파트너십은 전통적인 고처리량 스크리닝 컬렉션보다 우수한 집중 라이브러리 생성을 가능하게 합니다.
연구 협력의 일환으로 Recursion은 내부 발견 필요를 위해 수만 개의 화합물에 접근할 수 있었고, 동시에 상업적 관심이 높은 라이브러리 개발을 도왔습니다. 큐레이션된 라이브러리는 이제 고객의 히트 찾기 캠페인을 위해 Enamine의 웹사이트를 통해 이용 가능합니다.
Recursion (NASDAQ: RXRX) et Enamine ont annoncé une collaboration pour créer des bibliothèques de composés ciblés activées par l'IA pour la découverte de médicaments. Ce partenariat combine la plateforme AI/ML de Recursion (Recursion OS) avec le REAL Space d'Enamine, la plus grande collection de petites molécules à la demande au monde.
Cette collaboration a abouti à 10 bibliothèques de criblage enrichies comprenant plus de 15 000 composés nouvellement synthétisés, conçues pour accélérer la découverte de médicaments contre 100 cibles cliniques clés dans des domaines biologiques difficiles. En tirant parti de la technologie IA de Recursion pour prédire la compatibilité des petites molécules avec les cibles protéiques, le partenariat permet la création de bibliothèques ciblées qui surpassent les collections traditionnelles de criblage à haut débit.
Dans le cadre de la collaboration de recherche, Recursion a eu accès à des dizaines de milliers de composés pour ses besoins internes de découverte, tout en aidant à développer des bibliothèques d'un large intérêt commercial. Les bibliothèques sélectionnées sont désormais disponibles sur le site Web d'Enamine pour les campagnes de recherche de hits des clients.
Recursion (NASDAQ: RXRX) und Enamine haben eine Zusammenarbeit angekündigt, um KI-gestützte gezielte Verbindungen für die Arzneimittelentdeckung zu erstellen. Die Partnerschaft kombiniert die KI/ML-Plattform von Recursion (Recursion OS) mit dem REAL Space von Enamine, der größten On-Demand-Sammlung kleiner Moleküle der Welt.
Die Zusammenarbeit hat zu 10 angereicherten Screening-Bibliotheken geführt, die aus über 15.000 neu synthetisierten Verbindungen bestehen und darauf ausgelegt sind, die Arzneimittelentdeckung gegen 100 wichtige klinische Ziele in herausfordernden biologischen Bereichen zu beschleunigen. Durch die Nutzung der KI-Technologie von Recursion zur Vorhersage der Kompatibilität kleiner Moleküle mit Protein-Zielen ermöglicht die Partnerschaft die Erstellung fokussierter Bibliotheken, die herkömmliche Hochdurchsatz-Screening-Kollektionen übertreffen.
Im Rahmen der Forschungszusammenarbeit erhielt Recursion Zugang zu Zehntausenden von Verbindungen für seine internen Entdeckungsbedürfnisse und half gleichzeitig bei der Entwicklung von Bibliotheken von breitem kommerziellen Interesse. Die kuratierten Bibliotheken sind jetzt über die Website von Enamine für Kundenkampagnen zur Hitfindung verfügbar.
- Creation of 10 new screening libraries with 15,000 compounds targeting 100 clinical targets
- Access to tens of thousands of additional compounds for internal discovery
- Potential for improved drug discovery efficiency through AI-enhanced compound selection
- Commercial availability of the new libraries through Enamine's platform
- None.
Insights
Recursion's partnership with Enamine represents a strategic advancement in AI-driven drug discovery that should strengthen RXRX's competitive position in the TechBio space. By leveraging their Recursion OS platform to navigate Enamine's vast REAL Space of tens of billions of possible compounds, they've created 10 focused libraries targeting 100 key drug targets in challenging biological areas.
The value proposition is clear: these AI-curated libraries can outperform traditional high-throughput screening collections by identifying promising compounds with higher precision. For Recursion, this collaboration delivers two tangible benefits: (1) access to tens of thousands of new compounds for their internal pipeline that their platform predicts may have specific biological interactions, and (2) commercialization potential through Enamine's distribution of these targeted libraries to pharmaceutical customers.
This development aligns with Recursion's business model of monetizing their AI platform while simultaneously enhancing their own drug discovery capabilities. While financial terms weren't disclosed, this represents practical application of Recursion's technology platform that could accelerate hit identification across multiple therapeutic areas. The partnership demonstrates how Recursion continues to leverage its computational approach to solve fundamental drug discovery challenges, potentially reducing time and resources needed in early-stage pharmaceutical research.
Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine's REAL Space, the world’s largest source of make-on-demand small molecules. Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized compounds designed to accelerate drug discovery against 100 key and clinically relevant drug targets in difficult to address biological areas.
Enamine’s REAL Space represents the continuously expanding chemical library built on insights from millions of parallel syntheses. While the chemical space offers incredible potential, the sheer volume of compounds, numbering in the tens of billions, makes it difficult to select the most promising candidates. By combining the expansive REAL Space with the Recursion OS to predict small molecule compatibility with protein targets, the collaboration allows for the creation of smaller, highly focused libraries that outperform traditional high-throughput screening (HTS) collections.
"We have been using the Recursion OS to identify compounds across Enamine’s vast chemical space for our own internal discovery needs," said Chris Gibson Co-Founder and CEO of Recursion. "This collaboration allows us to extend that approach to areas of biology that are of general interest to the industry. We are bringing together the best of both worlds—Enamine’s vast chemical library and Recursion’s AI-driven drug discovery platform to help expand the drug discovery toolset."
These curated compound libraries are an output of a research collaboration between Recursion and Enamine, whereby Recursion gained access to tens of thousands of compounds that it individually predicted may interact with the functional areas of biology not addressed by its current 1.2M compound library in exchange for helping to develop libraries of broad commercial interest.
“Enamine’s REAL has enormous discovery opportunities. While it has previously been utilized in ultra-large virtual screening campaigns, it has never been explored at scale across multiple targets. Our partnership with Recursion allows us to tap into their cutting-edge technology to rapidly uncover novel compounds with high potential in various research fields rapidly. We are ready to launch this new generation of compound libraries to support our customers’ hit-finding campaigns, secured by rapid access to analogues from REAL,” added Andrey Tolmachov, CEO and Founder of Enamine.
For more information about the curated compound libraries, visit Enamine’s website here: https://enamine.net/compound-libraries
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.
About Enamine
Enamine is a scientifically driven integrated discovery Contract Research Organisation with unique partnering opportunities in exploring new chemical space. The company combines access to the in-house produced screening compounds (4.5M in stock) and building blocks (350K in stock) with a comprehensive platform of integrated discovery services to advance and accelerate the efforts in Drug Discovery. For more information visit: https://enamine.net
About Enamine REAL® Space
Enamine REAL® Space contains 64.9 billion make-on-demand molecules that can be synthesized at Enamine extremely fast (3-4 weeks), with high feasibility (over
For more information about the new collaboration or to learn more about the curated compound libraries, please contact:
Contact Information
Yurii Moroz, PhD
VP of Sales and Marketing, Enamine
y.moroz@enamine.net
https://enamine.net
Forward-Looking Statements
This document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the collaboration with Enamine and the ability to enhance the precision, speed, and efficiency of drug discovery efforts; Recursion’s leadership of the TechBio space; the Recursion OS and other technologies; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2024. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.
Media Contact Media@Recursion.com Investor Contact Investor@Recursion.com
FAQ
What is the scope of the Recursion (RXRX) and Enamine collaboration in 2025?
How does Recursion (RXRX) enhance drug discovery through the Enamine partnership?
What benefits does RXRX receive from the Enamine collaboration?
How are the new RXRX-Enamine compound libraries being commercialized?
